Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation

Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-Abl(T315I) protein has become a potential strategy to overcome drug resistance. Herein, we...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Acta Pharm Sin B
Päätekijät: Jiang, Liang, Wang, Yuting, Li, Qian, Tu, Zhengchao, Zhu, Sihua, Tu, Sanfang, Zhang, Zhang, Ding, Ke, Lu, Xiaoyun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2021
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8148061/
https://ncbi.nlm.nih.gov/pubmed/34094836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2020.11.009
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia